Health, risks and disease in therapeutic functionalities of Glucagon-like peptide-1 receptoragonists (GLP-1RAs) concerning human susceptibility

Abstract

This review expounds the unique sphere of medical care as it ardently advances the therapeutic concerns and essentials of GLP-1 drugs per the risk of inappropriate lean mass loss, possible resultant sarcopenia, with special reference in elderly or frail persons, irrespective of the beneficial outcomes of weight loss in chronic perturbations, such as type 2 diabetes, obesity, comorbidities, cardiovascular and neurodegenerative disorders. It is significant to have protective stances on muscle quality. The proportional augmentation of muscle lost with GLP-1 usage requires inter alia resistance training, high protein consumption, and potential medication research to ameliorate muscle wasting. These highlight the pertinence for an equilibrated modality to obesity, type 2 diabetes and cardiovascular disease management, incorporating lifestyle changes for the sustainability and preservation regarding the functional status and stance as well as the quality of life. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are comprehensively utilized for the improvement of glycemic regulation and inducement of weight loss in type 2 diabetes (T2D), however, therapeutic outcomes vary tremendously among patients. GLP-1 receptor agonists (GLP-1 RAs) are being advanced from diabetes and obesity therapeutic regimen to novel spheres for disparate emerging conditions, encompassing cardiovascular, hepatic, neurodegenerative, and autoimmune perturbations, and may provide benefits in attenuating muscle dissipation by lean muscle mass preservation, although human data are anecdotal necessitating ardent studies. GLP-1 drugs are not directly the causative agents in muscle shrinkage, however, the prominent weight loss these drugs potentiate may preponderate to the dissipation of lean body mass, including muscle. The muscle loss may exacerbate in persons with pre-existing sarcopenia or other untoward health states. Although, certain muscle loss is inherent to an extent of accelerated weight loss, it is conducive to realise that the access to resistance training and proper protein intake in patients, vulnerable or susceptible individuals may ameliorate this impact and cause weight loss to be safer and increasingly sustainable. Invariably, GLP-1 drugs are aetiologic agents in muscle shrinkage, concomitantly with accelerated weight dissipation as the body utilises both fat and muscle for energy, with certain research indicating lean body mass, in concert with muscle, responsible for appreciable amount of overall weight loss. In order for these to be averted, coupling of GLP-1 with a high-protein diet and resilient physical training or exercise for muscle mass preservation may be pertinent. The broad and progressive advantages of GLP-1 medicines, primordially emanated as therapeutic target developed for regulating blood glucose and weight which improved outcomes and good prognosis in persons presenting with heart, kidney, liver, arthritis, and sleep apnea dysfunctions. The actions mediated partly via anti-inflammatory and metabolic pathways, and certain benefits partly independent of the extent of weight loss. The role or function of GLP-1 receptor agonists encompass lowering of serum glucose concentration with concomitant management of metabolism in patients implicated.The emerging functionality of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) primordially developed for type 2 diabetes management, have evolved into prominence in obesity management, providing clinically purposeful and beneficial weight loss and numerous other clinical trials in health and disease for the future.